Mimetas BV

CN Bio develops a suite of benchtop single-and multi-organ microphysiological systems (MPS) called PhysioMimix that can model human tissue systems in a more complex way than regular cell cultures in the lab. The company uses microfluidics to nourish the tissue models and to simulate blood flow between organs. A drawback of OOC systems that CN Bio and LifeNet Health are aiming to overcome is that cell cultures often need to undergo validation steps to check that they can be used in OOCs, which can be costly and time-intensive. And according to CN Bio’s release, more than 60% of liver cell lots from a range of suppliers over a 5-year period didn’t meet the criteria for use in MPS assays. To tackle this obstacle, LifeNet Health supplies donated human cells that are already validated for use in OOC systems, which can let customers carry out more reproducible and reliable assays. According to the agreement, LifeNet Health’s validated liver cells will be available in CN Bio’s PhysioMimix range for studying non-alcoholic steatohepatitis (NASH). Specifically, CN Bio will select hepatocyte, stellate, and Kupffer cells that can maintain their function and phenotype for at least two weeks in 3D MPS culture. The cells can also be bought from LifeNet Health directly. “LifeNet Health and CN Bio share a commitment to helping researchers bring safer, more effective therapies to patients sooner, with no unnecessary animal testing,” said Tomasz Kostrzewski, chief scientific officer at CN Bio, in a public statement. “In our studies, LifeNet Health’s cells have consistently shown high success rates, and we are confident this will lead to more reliable, reproducible results.” googletag.cmd.push(function () { googletag.display('text-ad1'); }); The global market for OOCs is forecast to grow by around 34.1% between 2022 and 2030, according to Orion Market Research. It noted increasing mergers and acquisitions and pharma partnerships driving the growth of the space, with one key example being a partnership between Yokogawa Electric Corp and the OOC provider InSphero AG in 2020. More recently, the big pharma company Astellas expanded an ongoing partnership with the OOC firm Mimetas to improve its assays with automation and application support.

UTRECHT, The Netherlands--(BUSINESS WIRE)-- Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors. Both bring a wealth of executive, business and clinical development expertise from large pharmaceutical and innovative biotech companies as Sapreme now builds upon preclinical proof of concept in several disease indications and delivery models. “We value the breadth and depth of Andre’s and Jeanne’s expertise and track record as Sapreme continues to grow and deliver on the potential of our technology. Their strategic guidance will be invaluable as we prepare for the next stages of corporate and scientific development for our endosomal escape technology platform and pipeline,” stated Guy Hermans, PhD, Chief Executive Officer of Sapreme. “I am looking forward to contributing to the advancement of Sapreme’s cutting-edge platform and its impact on the current therapeutic landscape. This technology is gaining recognition for its power for solving one of the most important challenges in large molecule pharmaceutical development to enable intracellular delivery and unlocking a vast number of disease targets,” commented Dr. Jeanne Bolger. Dr. Andre Hoekema added: “Sapreme’s proprietary technology has the potential to greatly improve efficacy of large molecules and therefore offers many business development opportunities with pharmaceutical and biotechnology companies in the field of RNA and antibodies, among others. It will be exciting to support the company in further expanding the ongoing strategic collaborations with these companies.” During her 35 years of experience in the pharmaceutical industry, Dr. Jeanne Bolger has acquired a wealth of knowledge and expertise in licensing, M&A, business development, alliance management and venture capital investments. She served as a non-executive director on the board of over a dozen life sciences companies in her role as Vice President Venture Investing at Johnson & Johnson Innovation-JJDC for over 10 years. Her expertise spans drug discovery and development in numerous therapeutic fields, including oncology, neurology, immunology, and gene therapy. Dr. Bolger is a registered medical doctor and holds an MB BCh in Medicine from University College Dublin. She currently sits on the board of Life Healthcare SA and is Chairperson of the board at ExeVir and at Astrivax. Dr. Andre Hoekema’s biotech career spans over four decades of senior positions overseeing corporate development including mergers and acquisitions, partnering and patent protection. Dr. Hoekema served as Chief Business Officer at Galapagos, Managing Director of Corporate Development Europe at Invitrogen Corporation, Managing Director at Molecular Probes Europe, and Director of Business Development at Crucell. He is an author in more than 30 peer-reviewed articles and has been granted more than 20 patents issued in the US and holds a PhD from Leiden University. Dr. Hoekema currently serves as board member of biotech companies Artax Biopharma, Fibrocor Therapeutics and Mimetas B.V. About Sapreme Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication. View source version on businesswire.com: Contacts For further inquiries, please contact: Guy Hermans, CEO +31 30 760 09 76 hermans@sapreme-technologies.com For Media Inquiries, please contact: Trophic Communications Desmond James or Eva-Maria Mulder +49 151 67859086 or +31 6 52 33 15 79 sapreme@trophic.eu Source: Sapreme View this news release online at:

BANGALORE, India, May 10, 2023 /PRNewswire/ -- The Global Organ On Chip Market is Segmented by Type (Liver-on-a-chip, Kidney-on-a-chip, Lung-on-a-chip, Heart-on-a-chip, Intestine-on-a-chip, Brain-on-a-chip, Vessel-on-a-chip), by Application (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Cosmetics Industry): Global Opportunity Analysis and Industry Forecast, 2023-2029. It is published in Valuates Reports under the Pharmaceuticals & Biotech Category. The global Organ On Chip market revenue was USD 88 Million in 2022 and is forecast to a readjusted size of USD 621.2 Million by 2029 with a CAGR of 31.2% during the review period (2023-2029). The development of substitutes for animal testing models, the significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and the introduction of new products, and the rising number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers are the main factors driving the growth of Organ On Chip market. Download Free Sample TRENDS INFLUENCING THE GROWTH OF THE ORGAN ON CHIP MARKET: Globalization has increased worries about the spread of illnesses and highlighted the necessity for rapid and effective drug screening procedures. A high failure rate in clinical trials has rendered outdated methods to medication effectiveness and toxicity. Organ-on-a-chip has become a vital replacement for antiquated methods since it accurately simulates key organ properties and predicts medication pharmacokinetics in a more morally and effective way. This factor is expected to drive the growth of the Organ on the chip market. Buy Chapters Only Because the liver has high levels of drug-metabolizing enzymes that process the majority of drugs, the liver is susceptible to damage brought on by drugs. However, because the drug-metabolizing activities of hepatocytes cultured under standard static 2D cell culture conditions are lower than those of the human liver, it is challenging to assess these injuries in vitro. Contrarily, liver-on-a-chips are useful for preserving the hepatocytes' capacity to metabolize drugs. Additionally, liver-on-a-chips with biosensors that can measure cytokine and oxygen concentrations for real-time evaluation have been developed because the exposure time before the onset of injury varies with the drug. This advantage offered by liver-on-a-chip is in turn expected to drive the market growth. The fundamental benefit of these chips is that they can be produced at extremely little cost, allowing researchers to assess the effectiveness of various medication concentrations. This will enable the scientific study to go much more quickly with organs-on-chip technology. The initial set of testing may be carried out repeatedly without running the danger of running into financial issues throughout the development of a new medicine. Additionally, there wouldn't be any ethical problems associated with animal testing, which is currently a growing source of concern for society. Organs on chips would put a stop to the practice of raising test animals for medical research, which is a topic of increasing discussion. This factor is expected to drive the growth of the Organ on the chip market. View Full Report on Organ On Chip Market ORGAN ON CHIP MARKET SHARE ANALYSIS: Emulate, TissUse, Mimetas, CN Bio Innovations, Valo Health, and other leading companies are involved in the global organ-on-chip market. A share of around 58% is held by the top 5 manufacturers worldwide. The largest market is North America, with a share of around 42%, followed by Europe and Asia-Pacific, each of which has a share of over 50%. Buy Regional Report on North America Buy Regional Report on Asia Pacific Key Companies: Emulate TissUse Hesperos CN Bio Innovations Tara Biosystems Draper Laboratory Mimetas Nortis Micronit Microtechnologies B.V. Kirkstall Cherry Biotech SAS Else Kooi Laboratory Get Company Profiles Buy Now for Single User + Covid-19 Impact : SUBSCRIPTION We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans. SIMILAR REPORTS: - Human Organs-on-Chips market was valued at USD 67 million in 2022 and is anticipated to reach USD 158.1 million by 2029, witnessing a CAGR of 12.8% during the forecast period 2023-2029. - Organ Preservation Solutions market was valued at USD 141.4 million in 2022 and is anticipated to reach USD 246.5 million by 2029, witnessing a CAGR of 9.7% during the forecast period 2023-2029. - Artificial Tissue Chips Market - Organ Tumor Chip Market - Multiorgan-on-a-Chip Market - Microchips 3D Cell Culture Market - Organ Preservation Device Market - Organ Preservation market size is projected to reach USD 251.4 million by 2027, from USD 159.7 million in 2020, at a CAGR of 6.2% during 2021-2027. - Medical Bionic Implant & Artificial Organs market was valued at USD 17840 million in 2022 and is anticipated to reach USD 22570 million by 2029, witnessing a CAGR of 4.0% during the forecast period 2023-2029. - Tissue and Organ Transplantation Market - Organ Preservation Techniques Market - Organ Transplant Rejection Medication Market - Artificial Organs and Bionics market was valued at USD 9830 million in 2022 and is anticipated to reach USD 15080 million by 2029, witnessing a CAGR of 7.4% during the forecast period 2023-2029. - DNA sequencing market was estimated to be worth USD 15990 million in 2022 and is projected to grow to USD 59490 million by 2029, at a CAGR of 20.4% from 2023 to 2029. - Single Cell Sequencing Market - Blockchain in Genomics Industry - NGS Informatics and Clinical Genomics Market - Spatial Genomics & Transcriptomics market size is projected to reach USD 282.9 Million by 2028, from USD 184.2 Million in 2021, at a CAGR of 6.2% during 2022-2028. - Plant Genomics market was valued at USD 6709.4 million in 2022 and is anticipated to reach USD 8838.3 million by 2029, witnessing a CAGR of 4.7% during the forecast period 2023-2029. - Genomics In Cancer Care Industry - The global cell culture market accounted for USD 16,107.7 million in 2019 and is expected to reach USD 36,926.8 million by 2027, registering a CAGR of 10.9% from 2020 to 2027. - The Live Cell Imaging Market is anticipated to grow at the rate of 8.9% CAGR by 2027. - Bioinformatics Market Size is USD 8,614.29 Million in 2019, and is projected to reach USD 24,731.61 Million by 2027, growing at a CAGR of 13.4% from 2020 to 2027. - Bioinformatics Services market size is projected to reach USD 2967.1 Million by 2027, from USD 1468.2 Million in 2020, at a CAGR of 10.1% during 2021-2027. - Biopreservation Refrigerator Industry - Biopreservation Market is projected to grow at a rate of 9.2% CAGR by 2026. - Nutrigenomics market size is projected to reach USD 20990 Million by 2027, from USD 10770 Million in 2020, at a CAGR of 9.5% during 2021-2027. - The genetic testing market accounted for USD 12,682 Million in 2019, and is expected to reach USD 21,260 Million by 2027, registering a CAGR of 10.1% from 2020 to 2027. - The global cell separation technologies market size was valued at USD 8,639.20 Million in 2019 and is projected to reach USD 28,766.14 Million by 2027, registering a CAGR of 15.4% from 2020 to 2027. - The global tissue engineering market size was valued at USD 2374 Million in 2019 and is forecasted to reach a size of USD 6815 Million by 2027 at a CAGR of 14.2% from 2020 to 2027. - Laboratory Information Management System (LIMS) market size is projected to reach USD 1503.3 Million by 2028, from USD 889 Million in 2021, at a CAGR of 7.7% during 2022-2028. - The global cell therapy market accounted for USD 7,754.89 Million in 2019, and is expected to reach USD 48,115.40 Million by 2027, registering a CAGR of 25.6% from 2020 to 2027. - Laboratory Automation market size is projected to reach USD 5121.4 Million by 2028, from USD 3695.5 Million in 2021, at a CAGR of 4.3% during 2022-2028. - Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size is projected to reach USD 8514.8 Million by 2028, from USD 5180.8 Million in 2021, at a CAGR of 6.9% during 2022-2028. - The global metagenomics market was valued at USD 176 Million in 2017 and is expected to reach USD 523 Million by 2024 at a CAGR of 16.8% from 2018 to 2024. - Genomics Personalized Health market size is projected to reach USD 16780 Million by 2028, from USD 9232.4 Million in 2021, at a CAGR of 8.4% during 2022-2028. - China Agrigenomics Market Report & Forecast - Clinical Trial Management System (CTMS) Market size is projected to reach USD 2701.8 Million by 2027, from USD 1045 Million in 2020, at a CAGR of 14.5% during 2021-2027. Click here to see related reports on Organ on chip market ABOUT US: Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs. Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs. To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources. CONTACT US: Valuates Reports [email protected] For U.S. Toll-Free Call 1-(315)-215-3225 For IST Call +91-8040957137 WhatsApp: +91-9945648335 Website: Twitter - LinkedIn - Logo: SOURCE Valuates Reports